Analysis of:
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1 (content.nejm.org)
"In summary, THEY showed that the infusion of a clonal population of CD4+ T cells with specificity for a single tumor-associated antigen caused complete regression of a tumor. During regression of the tumor, this clone appears to have induced the patient's own T cells to respond to other antigens of...
Analysis of:
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders (bloodjournal.hematologylibrary.org)
Very preliminary but this agent may offer a targeted, more "natural" approach to the MPD's- Polycythemia Vera, Myelofibrosis and Primary thrombocytosis.
Analysis of:
Tight Rein on Blood Sugar Has No Heart Benefit (www.nytimes.com)
Tight Glucose control in type 2 diabetes mellitus did not result in improved survival and possibly had a negative impact.
Analysis of:
Sanofi-Aventis and Oxford Biomedica report encouraging Trovax(R) phase II trial results in Metastatic Renal Cancer (www.pipelinereview.com)
This immunotherapeutic agent in association with interleukin 2 or interferon may be effective in renal cell carcinoma (RCC). To be tested in a phase III trial (against what??)
Analysis of:
Positive data on Antisoma’s ASA404 presented at ASCO (www.pipelinereview.com)
That appears to be a well contructed phase III trial adds ASA404 or a placebo to Taxol/Carboplatin. Nothing exotic, endpoints are overall survival (OS) as well as OS in Squams and non Squams.
Analysis of:
Genetic Research May Help Pick Patients' Best Cancer Drugs (online.wsj.com)
Genetic profiling will tell us who should or should not receive particular anti neoplastic agents. This is "personalized" therapy that has been predicted x years.
Analysis of:
Drug Brings ImClone in From Cold (online.wsj.com)
Well we know that the lung cancer trial http://online.wsj.com/article/SB121227163771635641.html?mod=2_1566_topbox was a bust so far. What other "good news" do we await
Analysis of:
Erbitux Slightly Boosts Survival in Cancer Study (online.wsj.com)
Basically?? It's a bust until we see subset analysis. It is possible adenocarcinomas as well as non smokers will show better survival
Analysis of:
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia (bloodjournal.hematologylibrary.org)
Revlimid has activity in Chronic Lymphatic Leukemia (CLL) in addition to myeloma and myelodysplasia.
Analysis of:
Mixed Outcomes in Laparoscopy for Prostates (www.nytimes.com)
Higher recurrance rate???!!!